Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

More articles from Therapeutic Agents: Biological

  • Abstract LB-C08: Imipridone ONC212 induces apoptosis, suppresses autophagy and synergizes upon GRP132 knockdown or exposure to lactic acid in preclinical studies of the pancreatic cancer microenvironment
    Isacco Ferrarini, Aakash Jhaveri, Young Lee, Howard Safran, Lanlan Zhou, Wafik S El-Deiry
    Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) LB-C08; DOI: 10.1158/1535-7163.TARG-19-LB-C08
  • Abstract CN07-02: Immunotoxins targeting GPC3 for liver cancer
    Mitchell Ho, Bryan D Fleming, Tim F Greten, Ira Pastan
    Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) CN07-02; DOI: 10.1158/1535-7163.TARG-19-CN07-02
  • Abstract LB-C07: Preclinical evaluation of MCLA-129: A bispecific antibody targeting c-MET and EGFR
    Cecile Geuijen, Mario di Matteo, Tristan Gallenne, Sarah Trusso Cafarello, Roy Nijhuis, Therese Visser, Willem Bartelink, Carina Bartelink-Clements, Berina Eppink, Rinse Klooster, John dekruif, Massimiliano Mazzone, Mark Throsby
    Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) LB-C07; DOI: 10.1158/1535-7163.TARG-19-LB-C07
  • Abstract CN01-02: Maximizing the potential of bispecific antibodies for cancer drug development
    Paul W H I Parren
    Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) CN01-02; DOI: 10.1158/1535-7163.TARG-19-CN01-02
  • Abstract C031: Ras processing by RRSP protease as a strategy to inhibit Ras-driven tumors
    Vania Vidimar, Greg L Beilhartz, Roman A Melnyk, Karla JF Satchell
    Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C031; DOI: 10.1158/1535-7163.TARG-19-C031
  • Abstract C026: DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, demonstrates potent antitumor activity in preclinical models
    Daisuke Okajima, Junko Yamaguchi, Michiko Kitamura, Reiko Kamei, Takanori Maejima, Tomoko Shibutani, Satoru Yasuda, Tadashi Toki, Tsuyoshi Karibe, Tomomichi Fujitani, Takashi Nakada, Riki Goto, Yutaka Noguchi, Yuki Abe, Toshinori Agatsuma
    Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C026; DOI: 10.1158/1535-7163.TARG-19-C026
  • Abstract C032: A novel integrin-targeted therapeutic agent for ovarian cancer
    Franics S Markland, Steve Swenson, Radu Minea, Louis Dubeau
    Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C032; DOI: 10.1158/1535-7163.TARG-19-C032
  • Abstract C027: A Phase I, dose finding study of BI 754111, an anti-LAG-3 antibody, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumors: preliminary results from the microsatellite stable (MSS) metastatic colorectal cancer (mCRC) cohort
    Johanna Bendell, Susanna V Ulahannan, Quincy Chu, Manish Patel, Ben George, Renee Landsberg, Mabrouk Elgadi, Christine Duffy, Ralph Graeser, Wenbo Tang, Michael Merger, Miaomiao Ge, Melissa Johnson
    Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C027; DOI: 10.1158/1535-7163.TARG-19-C027
  • Abstract C034: Cancer-specific intracellular delivery of therapeutic antibodies against RAS
    Michael J McGuire, Susan Li, Curtis A Allred, Indu Venugopal, Claire Gormley, Kathlynn C Brown
    Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C034; DOI: 10.1158/1535-7163.TARG-19-C034
  • Abstract C033: HPN328: An anti-DLL3 T cell engager for treatment of small cell lung cancer
    Wade H Aaron, Richard Austin, Manasi Barath, Evan Callihan, Michael Cremin, Thomas Evans, Maria Gamez, Vaishnavi Ganti, Golzar Hemmati, Kathryn Kwant, Che-Leung Law, Bryan Lemon, Llewelyn Lao, Mary Ellen Molloy, Jessica O’Rear, Laura Sun, Holger Wesche, Stephen Yu, Timothy Yu
    Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C033; DOI: 10.1158/1535-7163.TARG-19-C033

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 12
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement